Search Results

Keywords: epidiolex

UK to legalize CBD-based products as medicine

October 12, 2016 · Updated July 31, 2018

The United Kingdom’s top medical products regulatory authority has ruled that CBD and products containing the cannabis compound will now be treated as medicine. The announcement, however, doesn’t mean consumers will suddenly be able to buy CBD-infused products. Medicine makers will have to prove their CBD products meet safety, quality and effectiveness standards, the BBC […]

Read More

Week in Review: MassRoots’ woes, GW Pharma’s good news & pro-legalization polls

September 30, 2016 · Updated August 15, 2019

By Omar Sacirbey and John Schroyer MassRoots lands in financial hot water, GW Pharmaceuticals takes a step closer to winning U.S. approval for its marijuana-based drug, and a political veteran urges caution heading into the elections. Here’s a closer look at some notable developments in the marijuana industry over the past week.

Read More

GW Pharma’s latest clinical trial successful, stock soars

September 27, 2016 · Updated October 4, 2016

British cannabis company GW Pharmaceuticals has conducted a successful clinical trial in which it treated epileptic children with one of its marijuana-based drugs, triggering a surge in the company’s stock price. According to Reuters, tested doses of GW Pharmaceutical’s drug Epidiolex “were found to have induced a statistically significant improvement in reducing seizures” in patients […]

Read More

Week in Review: California is official, GW’s epilepsy drug & Illinois resignation

July 1, 2016 · Updated November 1, 2016

By Omar Sacirbey and John Schroyer California’s recreational marijuana campaign makes the November ballot, GW Pharmaceuticals’ MJ-based epilepsy drug could play a role in DEA rescheduling, and a possible new dawn in Illinois’ medical cannabis program. Here’s a closer look at some notable developments in the marijuana industry over the past week.

Read More

Medical Cannabis Company GW Pharma’s Stock Again Jumps

June 27, 2016

GW Pharmaceuticals – a publicly traded British medical cannabis company conducting clinical trials to determine how effective its medications are against epilepsy – watched its stock surge once again in response to a successful round of testing. News Monday that a phase 3 trial was helpful at treating patients with Lennox-Gastaut Syndrome, a type of epilepsy, […]

Read More

FDA Grants U.K. Firm Incentives to Develop Cannabis-Based Drug

April 25, 2016

U.S. regulators granted GW Pharmaceuticals’ cannabis-based epilepsy drug “orphan” status, enabling the company to receive tax credits and other incentives so it can test the drug on patients with a rare form of the disorder. The U.S. Food and Drug Administration’s decision gives British-based GW the green light to test its Epidiolex medicine for treating […]

Read More

GW Pharmaceuticals Could Make Major Splash in U.S. Cannabis Industry

March 30, 2016

By Omar Sacirbey A British company that develops cannabis-based medicine is on the verge of a major breakthrough that could ripple across the U.S. marijuana industry. GW Pharmaceuticals will likely seek FDA approval in the fourth quarter of this year to sell an epilepsy drug derived from marijuana, according to an analyst who follows the company.

Read More

Study Results Send GW Pharma’s Stock Soaring

March 14, 2016

A British maker of cannabis-based drugs revealed some sorely needed good news on Monday, announcing that an epilepsy medicine it created has successfully treated a severe form of epilepsy in children, according to Reuters. In a clinical study, GW Pharmaceuticals said its Epidiolex syrup reduced the monthly number of seizures in children with Dravet’s Syndrome by […]

Read More

GW Pharma Boosts Production in Expectation of FDA Approval

December 9, 2015 · Updated December 10, 2015

GW Pharmaceuticals is reportedly increasing its manufacturing capacity for medical marijuana and a specific cannabis-based drug it has developed for epileptics called Epidiolex. The British company is boosting production in anticipation of getting the green light from the U.S. Food and Drug Administration next year or in early 2017 to begin widespread distribution in the United […]

Read More